Posters

Evaluation of corneal endothelial integrity after intracameral injection of bevacizumab for rubeosis iridis cases

Poster Details

First Author: A.Rashed EGYPT

Co Author(s):                        

Abstract Details

Purpose:

Evaluate the corneal endothelium by specular microscopy before and after injection of bevacizumab in patients with rubeosis iridis in neovascular glaucoma. Monitor the change in endothelial cell density count(CD),coefficient of variation (CV) in cell size,and corneal thickness in a period of 1 week,1 month,and 6 months post injection.

Setting:

Opthalmology Department,Faculty of Medicine,Cairo University, Egypt

Methods:

Twenty five eyes of 25 consecutive patients with rubeosis iridis, referred to Ophthalmology Department in Kasr El Eini Hospitals, were recruited in this prospective study. Exclusion Criteria:Patients with decompensted corneal endothelium or low endothelial cell count, or with anterior chamber intraocular lenses.Treatment was scheduled between 1 and 4 days after.Limbal paracentesis was performed by an insulin syringe, then injection of 1mg (0.04ml) of bevacizumab into the anterior chamber, followed by prescription of oral acetazolamide 500mg tablets.Follow up was arranged at 1 week, 1, 3, and 6 months’ interval following injection. At each visit specular microscopy and intraocular pressure(IOP) was measured.

Results:

Endothelial cell count showed no marked drop in count during the whole follow up periods.It dropped from 92% of cases with good count to 83% after 6 months. Regarding the CV of cell size there was no significant change. Regarding the corneal thickness,corneal edema developed in 2 eyes at 1 week follow up with increase in corneal thickness,but resolved gradually with medication and time. Regarding the IOP, it was consistently lower after injection during the whole follow up period (P=0.05)

Conclusions:

Although bevacizumab is showing a promising strategy as an adjunctive treatment of anterior segment neovascularization,with no effect on corneal endothelial integrity,however; there is still a need for controlled prospective trials to establish long-term safety, efficacy, and dosing guidelines for this treatment modality.

Financial Disclosure:

NONE